New treatments for viral respiratory tract infections - Opportunities and problems

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 3, 2001, Pages 251-259

  Snell, N J C ^a  

^a Bayer Pharma   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AG 270201; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BAY Z 9700; BETA INTERFERON; CIDOFOVIR; CL 387626; CROFELEMER; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HEMAGGLUTININ; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; ISATORIBINE; NARI 10146; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; PLACEBO; PLECONARIL; PROTEINASE INHIBITOR; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; RIBAVIRIN; RIMANTADINE; RUPINTRIVIR; SIALIDASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VP 14637; WIN 63483; ZANAMIVIR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONAVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; HANTAVIRUS; HERPES ZOSTER; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALER; MOUSE; NEBULIZATION; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PAPILLOMA VIRUS; PAPILLOMATOSIS; PARAINFLUENZA VIRUS; POSTOPERATIVE INFECTION; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS; SIDE EFFECT; SYMPTOMATOLOGY; VIRUS INFECTION; VIRUS PNEUMONIA;

EID: 0035090556     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.3.251     Document Type: Review

References (110)

1. Implications of the Relenza ruling
2. Epidemiology, pathogenesis, and treatment of the common cold
3. Croup
4. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease
5. Viruses and asthma
6. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis
7. Respiratory syncytial virus infection
8. Impact of respiratory virus infections on persons with chronic underlying conditions
9. Respiratory viral infections in immunocompetent and immunocompromised persons
10. Conventional respiratory viruses recovered from immunocompromised patients: Clinical considerations
11. HIV infection increases susceptibility to smoking-induced emphysema
12. Hantavirus pulmonary syndrome in the Americas: The early years
13. Viruses and idiopathic pulmonary fibrosis
14. Latent adenoviral infection in the pathogenesis of chronic airways obstruction
15. Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis
16. The role of viruses in the pathogenesis of hypersensitivity pneumonitis
17. The efficacy and tolerance of intranasal interferons: Studies at the Common Cold Unit
18. The canyon hypothesis
19. Antiviral agent blocks breathing of the common cold virus
20. De novo pediatric development of an antiviral drug product: A perspective from industry
21. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection
22. Pleconaril
23. Pleconaril shortens duration of picornaviral upper respiratory tract illness in adults
24. Design of rhinovirus protease inhibitors for the treatment of the common cold
25. Rhinovirus and their ICAM receptors
26. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection
27. Efficacy of tremacamra, a soluble intercellular adhesion molecule I, for experimental rhinovirus infections
28. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1
29. Why aren't antivirals effective when administered intranasally?
30. A study of the efficacy of the immunomodulatory compound 7-thia-8-oxoguanosine in coronavirus 229E infections in human volunteers
31. 11C]zanamivir following administration as an intranasal spray
32. Delivery of peptide and non-peptide drugs through the respiratory tract
33. Chemotherapeutic control of influenza
34. Amantadine blocks the channel
35. Comparison of central nervous system effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients
36. Chemotherapy of respiratory viruses
37. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double-blind, multi-centre, placebo-controlled trial
38. Targeting influenza viral neuraminidase - A new strategy for antiviral therapy
39. Recent developments in sialidase inhibitors for the treatment of influenza
40. Influenza virus neuraminidase inhibitors
41. The clinical benefits of zanamivir in influenza
42. Oseltamivir
43. Inhaled zanamivir for the prevention of influenza in families
44. Efficacy of inhaled zanamivir in reducing complications and antibiotic use in influenza-results of phase II and III clinical studies
45. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation
46. The impact of oseltamivir treatment on upper and lower respiratory tract complications of acute influenza in children
47. Respiratory distress associated with zanamivir
48. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir
49. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based design
50. Investigation of substituted pyrrolidine influenza neuraminidase inhibitors: SAR of a series of secondary alcohols
51. In vitro and in vivo activity of a series of influenza A inhibitors derived from podocarpic acid
52. In vitro and in vivo anti-influenza A virus activity of antisense oligonucleotides
53. Influenza virus-inhibitory effects of intraperitoneally and aerosol-administered SP-303, a plant flavenoid
54. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections
55. Advances in prevention of respiratory syncytial virus infections
56. Palivizumab: An overview
57. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein
58. Prevention of respiratory syncytial virus infection with palivizumab
59. Safety and tolerance of nebulised ribavirin in clinical usage
60. Ribavirin for RSV lower respiratory tract infection: A systematic overview
61. Management strategies for respiratory syncytial viral infections in infants
62. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected RSV infection
63. Respiratory syncytial virus: Recent progress towards the discovery of effective prophylactic and therapeutic agents
64. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a
65. Children's respiratory viral diseases treated with interferon aerosol
66. Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agents
67. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
68. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle
69. Recurrent respiratory papillomatosis: Juvenile versus adult forms
70. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1
71. Pilot trial of ribavirin for the treatment of laryngeal papillomatosis
72. Acyclovir in the treatment of recurrent respiratory papillomatosis: A preliminary report
73. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir
74. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir
75. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of haemorrhagic fever with renal syndrome
76. Intravenous ribavirin for hantavirus pulmonary syndrome: Safety and tolerance during one year of open label experience
77. The clinical evaluation of agents for the prophylaxis and treatment of viral infections of the respiratory tract
78. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV
79. Prevention and treatment of influenza in immunocompromised patients
80. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients
81. Failure of intravenous ribavirin in the treatment of invasive adenovirus infection following allogeneic bone marrow transplantation: A case report
82. Management of herpes virus infections following transplantation
83. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
84. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immuno-suppression phase following lung transplantation
85. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
86. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
87. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
88. A protein-based therapeutic for human cytomegalovirus infection
89. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leucocyte interferon
90. Herpes simplex virus infection in heart-lung transplant recipients
91. Resistance to antiviral drugs: The end of innocence
92. 2 strain resistant to amantadine
93. Children with influenza A infection: Treatment with rimantadine
94. Resistance to rimantadine and amantadine
95. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine
96. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients
97. Low incidence of rimantadine resistance to field isolates of influenza A viruses
98. Molecular mechanisms of action of ribavirin
99. Influenza virus resistance to neuraminidase inhibitors
100. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
101. Evidence for zanamivir resistance in an immuno-compromised child infected with influenza B virus
102. Drug resistance of herpes viruses: A clinical problem or not?
103. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation
104. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalo-virus disease
105. Molecular basis of drug resistance to new antirhinovirus agents
106. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro
107. In vitro inhibitory effects of combinations of anti-influenza agents